US healthcare professionals can visit sotaloliv.com for more product information.
Cardiac arrhythmias — including atrial fibrillation, atrial flutter, and life-threatening ventricular tachycardia — represent one of the most serious and costly areas of cardiovascular medicine. AltaThera specializes in developing intravenous therapies that address the gaps in how these conditions are treated, giving physicians faster, more precise tools to personalize care for patients who need it most.
It is indicated for:
Limitations of Use
In July 2025, the FDA approved a label expansion for Sotalol IV adding a pediatric indication. Read more about the pediatric approval →
Full prescribing information for Sotalol IV including boxed warning, contraindications, and dosing for adult and pediatric patients, is available here.
US healthcare professionals can view clinical information on Sotalol IV & how to order at sotaloliv.com →
Intravenous drug initiation offers clinical advantages that oral administration cannot match — particularly in the context of antiarrhythmic therapy, where speed of assessment and precision of dosing are critical.
In adults, Sotalol IV reaches maximum serum concentration in 1 hour, enabling physicians to quickly assess a patient's response to therapy at chosen therapeutic levels.1
In adult patients, Sotalol IV offers the potential for outpatient discharge in under 24 hours, based on renal function, clinical evaluation, response to therapy1 — compared to the minimum 3-day inpatient stay required for oral sotalol initiation.2
Shorter stays mean reduced burden on hospital beds, nursing resources, and ancillary services — benefits that extend beyond the individual patient to the health systems that care for them.
Intravenous therapy offers precise dosing for pediatric patients, who historically have less options available for them. Sotalol IV is FDA-approved for use in pediatrics1 — offering rhythm control for pediatric physicians.
Peer-reviewed research supports these clinical benefits. View publications on intravenous sotalol on our Research page →
AltaThera is at the forefront of antiarrhythmic medicine. We partner with physicians and health systems to address the therapeutic challenges that existing oral treatments cannot fully solve — focusing our science on the patients and settings where intravenous therapy makes the greatest difference.
While Sotalol IV is our first product, our scientific pipeline is actively exploring new indications, patient populations, and drug delivery approaches in cardiovascular medicine. Our goal is to build a portfolio of intravenous therapies that expand access to personalized cardiac care.
Highlights of Prescribing Information
Boxed Warning, Indications, and Important Safety Information
WARNING: LIFE THREATENING PROARRHYTHMIA
Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. To minimize the risk of drug induced arrhythmia, initiate or uptitrate intravenous sotalol in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)].
Do not initiate intravenous sotalol therapy if the baseline QTc is longer than 450 ms. If the QTc prolongs to 500 ms or greater, reduce the dose or discontinue.